Literature DB >> 28600623

Fibrin-specific and effective clot lysis requires both plasminogen activators and for them to be in a sequential rather than simultaneous combination.

R Pannell1, S Li1, V Gurewich2.   

Abstract

Thrombolysis with tissue plasminogen activator (tPA) has been a disappointment and has now been replaced by an endovascular procedure whenever possible. Nevertheless, thrombolysis remains the only means by which circulation in a thrombosed artery can be restored rapidly. In contrast to tPA monotherapy, endogenous fibrinolysis uses both tPA and urokinase plasminogen activator (uPA), whose native form is a proenzyme, prouPA. This combination is remarkably effective as evidenced by the fibrin degradation product, D-dimer, which is invariably present in plasma. The two activators have complementary mechanisms of plasminogen activation and are synergistic in combination. Since tPA initiates fibrinolysis when released from the vessel wall and prouPA is in the blood, they induce fibrinolysis sequentially. It was postulated that this may be more effective and fibrin-specific. The hypothesis was tested in a model of clot lysis in plasma in which a clot was first exposed to tPA for 5 min, washed and incubated with prouPA. Lysis was compared with that of clots incubated with both activators simultaneously. The sequential combination was almost twice as effective and caused less fibrinogenolysis than the simultaneous combination (p < 0.0001) despite having significantly less tPA, as a result of the wash. A mechanism is described by which this phenomenon can be explained. The findings are believed to have significant therapeutic implications.

Entities:  

Keywords:  Fibrinolysis; ProuPA; Sequential lysis; Synergy; tPA

Mesh:

Substances:

Year:  2017        PMID: 28600623     DOI: 10.1007/s11239-017-1514-0

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  21 in total

1.  Prourokinase mutant that induces highly effective clot lysis without interfering with hemostasis.

Authors:  Jian-Ning Liu; Jian-Xia Liu; Bei-fang Liu Bf; Ziyong Sun; Jian-Ling Zuo; Pei-xiang Zhang Px; Jing Zhang; Yu-hong Chen Yh; Victor Gurewich
Journal:  Circ Res       Date:  2002-04-19       Impact factor: 17.367

2.  A transitional state of pro-urokinase that has a higher catalytic efficiency against glu-plasminogen than urokinase.

Authors:  J N Liu; R Pannell; V Gurewich
Journal:  J Biol Chem       Date:  1992-08-05       Impact factor: 5.157

3.  Urokinase-type plasminogen activator is effective in fibrin clearance in the absence of its receptor or tissue-type plasminogen activator.

Authors:  T H Bugge; M J Flick; M J Danton; C C Daugherty; J Romer; K Dano; P Carmeliet; D Collen; J L Degen
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-11       Impact factor: 11.205

4.  Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin.

Authors:  M Hoylaerts; D C Rijken; H R Lijnen; D Collen
Journal:  J Biol Chem       Date:  1982-03-25       Impact factor: 5.157

5.  Synergism of tissue-type plasminogen activator (t-PA) and single-chain urokinase-type plasminogen activator (scu-PA) on clot lysis in vitro and a mechanism for this effect.

Authors:  V Gurewich; R Pannell
Journal:  Thromb Haemost       Date:  1987-06-03       Impact factor: 5.249

6.  A site-directed mutagenesis of pro-urokinase which substantially reduces its intrinsic activity.

Authors:  J N Liu; W Tang; Z Y Sun; W Kung; R Pannell; P Sarmientos; V Gurewich
Journal:  Biochemistry       Date:  1996-11-12       Impact factor: 3.162

7.  The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction.

Authors: 
Journal:  N Engl J Med       Date:  1993-11-25       Impact factor: 91.245

8.  Fibrinolytic activity of normal human blood monocytes.

Authors:  E Grau; L A Moroz
Journal:  Thromb Res       Date:  1989-01-15       Impact factor: 3.944

9.  Tissue plasminogen activator and urokinase mediate the binding of Glu-plasminogen to plasma fibrin I. Evidence for new binding sites in plasmin-degraded fibrin I.

Authors:  P C Harpel; T S Chang; E Verderber
Journal:  J Biol Chem       Date:  1985-04-10       Impact factor: 5.157

10.  A comparative study of the promotion of tissue plasminogen activator and pro-urokinase-induced plasminogen activation by fragments D and E-2 of fibrin.

Authors:  J N Liu; V Gurewich
Journal:  J Clin Invest       Date:  1991-12       Impact factor: 14.808

View more
  1 in total

1.  An in vitro Model System for Evaluating Remote Magnetic Nanoparticle Movement and Fibrinolysis.

Authors:  Sebastian P Pernal; Alexander J Willis; Michael E Sabo; Laura M Moore; Steven T Olson; Sean C Morris; Francis M Creighton; Herbert H Engelhard
Journal:  Int J Nanomedicine       Date:  2020-03-09
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.